Targeted Disease(s):
Other
Purpose of Study:
The AIRTIVITY® Study is looking to see if an investigational medicine – designed to target the harmful inflammation that contributes to bronchiectasis – can help improve the lives of people living with the condition.
Study Dates:
June 9, 2025 - September 12, 2028
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Boehringer Ingelheim Pharmaceuticals, Inc.
Contact:
800-243-0127
clintriage.rdg@boehringer-ingelheim.com
ClinicalTrails.gov Identifier:
NTC06872892
